haloperidol has been researched along with Body Weight in 141 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder." | 9.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| " Recent data indicate that the atypical antipsychotic clozapine, but not the typical antipsychotic haloperidol, decreases alcohol drinking both in patients with schizophrenia and also in the Syrian golden hamster, an animal model of moderate alcohol drinking." | 7.79 | The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. ( Ahmed, J; Chau, DT; Dawson, R; Green, AI; Khokhar, JY; Xie, H, 2013) |
| "Both antipsychotic drugs cause sex-dependent metabolic changes, which are risk factors for the metabolic syndrome, be it hyperinsulinemia under haloperidol treatment or hyperglycemia, hyperleptinemia and hyperlipidemia under clozapine." | 7.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 7.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 7.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "This study was designed to investigate the effects of two doses of haloperidol on body weight, food spillage and food and water intake using rats as subjects." | 7.66 | Effects of chronic haloperidol treatment on ingestive behaviour and body weight regulation in the rat. ( Uguru-Okorie, DC, 1981) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 6.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| " The objective of this study was to examine the antipsychotic effect and side effect profile of amoxapine versus haloperidol in a double-blind study for 6 weeks in patients with schizophrenia." | 5.12 | Amoxapine as an antipsychotic: comparative study versus haloperidol. ( Badshah, S; Chaudhry, IB; Deakin, B; Husain, N; Kapur, S; Khan, S, 2007) |
| "Olanzapine has been hypothesized to have superior efficacy in patients with treatment-resistant schizophrenia." | 5.11 | Olanzapine treatment of residual positive and negative symptoms. ( Ball, MP; Buchanan, RW; Carpenter, WT; Gold, JM; Kirkpatrick, B; McMahon, RP; Weiner, E, 2005) |
| "Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder." | 5.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| " TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation." | 3.79 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. ( Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG, 2013) |
| " Recent data indicate that the atypical antipsychotic clozapine, but not the typical antipsychotic haloperidol, decreases alcohol drinking both in patients with schizophrenia and also in the Syrian golden hamster, an animal model of moderate alcohol drinking." | 3.79 | The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. ( Ahmed, J; Chau, DT; Dawson, R; Green, AI; Khokhar, JY; Xie, H, 2013) |
| "Both antipsychotic drugs cause sex-dependent metabolic changes, which are risk factors for the metabolic syndrome, be it hyperinsulinemia under haloperidol treatment or hyperglycemia, hyperleptinemia and hyperlipidemia under clozapine." | 3.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| "We investigated the effects of acute as well as subchronic administration of clozapine on food intake, body weight gain, glucose tolerance and insulin secretion in response to glucose in Sprague-Dawley rats." | 3.74 | Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. ( Bianchi, I; Cocchi, D; Fanzani, A; Rizzetti, C; Spano, P; Tulipano, G, 2007) |
| "5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition." | 3.73 | A model for antipsychotic-induced obesity in the male rat. ( de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D, 2006) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| " With the aim of evaluating whether the rat can be used as a model for antipsychotic-induced weight gain, we have investigated the effect of chronic treatment (3 weeks) with one antipsychotic drug inducing weight gain in clinic (olanzapine) and one antipsychotic not inducing weight gain in clinic (haloperidol), on food and water intake and body weight gain in rats." | 3.72 | Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. ( Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S, 2003) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 3.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| ") with haloperidol (HAL), a dopamine receptor antagonist for 6 or 9 months to produce hyperprolactinemia." | 3.70 | Effects of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons. ( Arbogast, L; MohanKumar, PS; MohanKumar, SM; Quadri, SK; Voogt, JL, 1998) |
| " More recently our laboratory has reported that prenatal exposure to haloperidol (HAL), a neuroleptic which binds to and blocks dopamine receptor sites in the adult brain, permanently stunts body and brain growth when that exposure extends throughout postimplantation pregnancy." | 3.69 | Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. ( Grafton, TF; Hansen, DK; Holson, RR; Webb, PJ, 1994) |
| "The long-term effects of haloperidol on weight were assessed in 30 children, 25 males and 5 females, diagnosed with autistic disorder whose ages ranged from 3." | 3.68 | Haloperidol withdrawal and weight changes in autistic children. ( Anderson, LT; Campbell, M; Malone, RP; Shay, J; Silva, RR, 1993) |
| "The probable roles of Acetylcholine (Ach) and Dopamine (DA) in the modulation of instinctual behaviors of feeding and hoarding (HS), as also the body weight and vaginal cyclicity (EI), were studied by instillation of Atropine (Ach antagonist), Haloperidol (DA antagonist) and Apomorphine (DA agonist) in the dorsal hippocampus of nonpregnant female rats." | 3.68 | Role of acetylcholine and dopamine in dorsal hippocampus on hoarding behavior in rats. ( Borker, AS; Mascarenhas, JF, 1991) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 3.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| " cocaine self-administration in the rat, three groups of rats were deprived of food to different extents in order to obtain body weight reductions of 5 to 15, 15 to 25 and 25 to 35% of the pre-experimental body weights, and were tested for five consecutive 6-hr sessions in a continuous reinforcement procedure for self-administration of cocaine (0." | 3.67 | Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol. ( De Vry, J; Donselaar, I; Van Ree, JM, 1989) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 2.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| " Chronic administration of haloperidol significantly increased oxidative stress and neuro-inflammation in the striatum region of the rat's brain." | 1.42 | Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. ( Bansal, PK; Bisht, R; Prakash, A; Thakur, KS, 2015) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| "Haloperidol treatment reduced the voluntary activity and energy expenditure of DR mice and induced insulin resistance in these mice." | 1.37 | Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. ( de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K, 2011) |
| " Various animal studies have demonstrated an enhanced oxidative stress and increased glutamatergic transmission as well as inhibition in the glutamate uptake after the chronic administration of haloperidol." | 1.35 | Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| " The present study compares the effect of chronic administration of typical and atypical antipsychotics on neurochemical profile in rat forebrain." | 1.34 | Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A, 2007) |
| " In the present work, we studied in male rats the effects of long-term administration of two neuroleptics: haloperidol, a classical neuroleptic which has a moderate effect on weight gain in humans, and olanzapine, an atypical neuroleptic which has a more important effect on weight gain." | 1.33 | Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. ( de Beaurepaire, R; Even, PC; Guesdon, B; Minet-Ringuet, J; Tomé, D, 2005) |
| "Haloperidol was given at a daily dose of 1 mg/kg." | 1.32 | Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellum. ( Braendgaard, H; Larsen, JO; Licht, RW; Smith, D, 2003) |
| " Chronic administration of these drugs, however, altered BDNF synthesis or release and expression of TrkB-immunoreactivity within the brain." | 1.31 | Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. ( Aloe, L; Angelucci, F; Mathé, AA, 2000) |
| " Weanling male CD rats (21 days old) were dosed for 30 d by gavage with vehicle (0." | 1.31 | Evaluation of the male pubertal assay's ability to detect thyroid inhibitors and dopaminergic agents. ( Carney, EW; Crissman, JW; Marty, MS, 2001) |
| "Weight gain is one side effect of many antipsychotic drugs (APDs)." | 1.31 | Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. ( Bubser, M; Deutch, AY; Fadel, J, 2002) |
| " In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios)." | 1.30 | Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. ( Chang, WH; Chang, YC; Hu, OY; Hu, WH; Jann, MW; Lane, HY; Lin, HN, 1997) |
| "Both haloperidol and clozapine treatment reduced the weight gain of the rats." | 1.29 | Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. ( Koch, T; Korf, J; Sebens, JB; Ter Horst, GJ, 1995) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| " This study compared the effects of short-term versus long-term administration of the DA antagonist, haloperidol, on cocaine place conditioning." | 1.29 | Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. ( DeCaprio, JL; Kosten, TA; Nestler, EJ, 1996) |
| "The present study used stereological methods to determine whether long-term administration of lithium, with or without haloperidol, affects the number and average volume of neocortical neurons." | 1.29 | Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex. ( Braendgaard, H; Larsen, JO; Licht, RW; Smith, D, 1994) |
| " However, there were no adverse effects on the copulation index in any of the treated groups." | 1.29 | Collaborative work to determine an optimal administration period and optimal parameters for detection of effects on male fertility in rats--male reproductive toxicity study of haloperidol. ( Imanishi, M; Takagi, S; Takeuchi, M; Yoneyama, M, 1995) |
| " Dose-response curves were determined at the conclusion of the chronic phase." | 1.28 | Sensitization to haloperidol-induced suppression of milk intake: effect of interdose interval. ( Moore, J; Wolgin, DL, 1992) |
| " Long-term administration induced distinctively different patterns of oral activity in the three drug groups, both in number of CSMs and the form of these movements." | 1.28 | Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. ( Ellison, G; See, RE, 1990) |
| " This study examined the effect of chronic administration of haloperidol, clozapine, sulpiride and metoclopramide on stereotypy and locomotor activity elicited by direct injection of dopamine in to the striatum or nucleus accumbens, respectively." | 1.28 | Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. ( Davis, KL; Guerin, JJ; Halperin, R, 1989) |
| " There was no significant difference in Li dosage among these three groups." | 1.28 | Effect of lithium and neuroleptic combination on lithium transport, blood pressure, and weight in bipolar patients. ( Ghadirian, AM; Nair, NP; Schwartz, G, 1989) |
| "Treatment of bromperidol caused sedation of pregnant females in 1." | 1.27 | [Teratogenicity study on bromperidol in rats]. ( Huang, KJ; Imai, S; Sudo, T; Takeshima, T; Tauchi, K, 1984) |
| "The effects of melanotropin release-inhibiting factor, a tripeptide (Pro-Leu-Gly-NH2) derived from the hypothalamus, and its enzymatically stable analog, cyclo(Leu-Gly) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to male Sprague-Dawley rats was determined." | 1.27 | Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats. ( Bhargava, HN, 1984) |
| "Substance P was not changed in these structures after either of the two drugs." | 1.27 | Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat. ( Nylander, I; Terenius, L, 1986) |
| " Chronic administration of sulpiride does not induce identical changes in striatal dopamine function to those caused by haloperidol." | 1.27 | Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. ( Fleminger, S; Hall, MD; Jenner, P; Kilpatrick, G; Mann, S; Marsden, CD; Rupniak, NM, 1984) |
| "Buspirone is a novel anti-anxiety drug which has neither a benzodiazepine structure nor any other benzodiazepine-like properties." | 1.27 | Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission. ( McMillen, BA, 1985) |
| "1-1 mg/kg SC) also produced jumping behavior, but the dose-response curve for apomorphine was shifted to the right." | 1.27 | Effects of acute and long-term treatments with thyrotropin-releasing hormone on locomotor activity and jumping behavior in mice. ( Glavin, GB; Hara, T; Hirano, H; Mizuki, Y; Ushijima, I; Watanabe, K; Yamada, M, 1986) |
| "Comparison has been made of the effects on brain dopamine function of chronic administration of haloperidol or clozapine to rats for up to 12 months." | 1.27 | Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. ( Fleminger, S; Hall, MD; Jenner, P; Kilpatrick, G; Mann, S; Marsden, CD; Rupniak, NM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (46.81) | 18.7374 |
| 1990's | 23 (16.31) | 18.2507 |
| 2000's | 38 (26.95) | 29.6817 |
| 2010's | 14 (9.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X | 1 |
| Zhang, Y | 1 |
| Chen, Y | 1 |
| Qiu, Y | 1 |
| Yu, M | 1 |
| Xu, X | 1 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, L | 1 |
| Zhang, G | 1 |
| Noaín, D | 1 |
| Pérez-Millán, MI | 1 |
| Bello, EP | 1 |
| Luque, GM | 1 |
| Casas Cordero, R | 1 |
| Gelman, DM | 1 |
| Peper, M | 1 |
| Tornadu, IG | 1 |
| Low, MJ | 1 |
| Becú-Villalobos, D | 1 |
| Rubinstein, M | 1 |
| Grover, S | 1 |
| Kumar, P | 1 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| Chau, DT | 1 |
| Khokhar, JY | 1 |
| Dawson, R | 1 |
| Ahmed, J | 1 |
| Xie, H | 1 |
| Green, AI | 1 |
| Thakur, KS | 1 |
| Prakash, A | 1 |
| Bisht, R | 1 |
| Bansal, PK | 1 |
| Robertson, SH | 1 |
| Boomhower, SR | 1 |
| Rasmussen, EB | 1 |
| Fiore, M | 1 |
| Di Fausto, V | 1 |
| Iannitelli, A | 1 |
| Aloe, L | 2 |
| Barakauskas, VE | 1 |
| Ypsilanti, AR | 1 |
| Barr, AM | 1 |
| Innis, SM | 1 |
| Honer, WG | 1 |
| Beasley, CL | 1 |
| Yamauchi, T | 1 |
| Tatsumi, K | 1 |
| Makinodan, M | 1 |
| Kimoto, S | 1 |
| Toritsuka, M | 1 |
| Okuda, H | 1 |
| Kishimoto, T | 1 |
| Wanaka, A | 1 |
| de Leeuw van Weenen, JE | 2 |
| Auvinen, HE | 1 |
| Parlevliet, ET | 2 |
| Coomans, CP | 1 |
| Schröder-van der Elst, JP | 2 |
| Meijer, OC | 1 |
| Pijl, H | 2 |
| Krakowski, M | 1 |
| Czobor, P | 1 |
| van den Berg, SA | 1 |
| Willems van Dijk, K | 1 |
| Romijn, JA | 1 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Revel, FG | 1 |
| Moreau, JL | 1 |
| Pouzet, B | 2 |
| Mory, R | 1 |
| Bradaia, A | 1 |
| Buchy, D | 1 |
| Metzler, V | 1 |
| Chaboz, S | 1 |
| Groebke Zbinden, K | 1 |
| Galley, G | 1 |
| Norcross, RD | 1 |
| Tuerck, D | 1 |
| Bruns, A | 1 |
| Morairty, SR | 1 |
| Kilduff, TS | 1 |
| Wallace, TL | 1 |
| Risterucci, C | 1 |
| Wettstein, JG | 1 |
| Hoener, MC | 1 |
| von Wilmsdorff, M | 1 |
| Bouvier, ML | 1 |
| Henning, U | 1 |
| Schmitt, A | 1 |
| Schneider-Axmann, T | 1 |
| Gaebel, W | 1 |
| Fadel, J | 1 |
| Bubser, M | 1 |
| Deutch, AY | 1 |
| Kane, JM | 1 |
| Carson, WH | 1 |
| Saha, AR | 1 |
| McQuade, RD | 1 |
| Ingenito, GG | 1 |
| Zimbroff, DL | 1 |
| Ali, MW | 1 |
| Lonstein, JS | 1 |
| Chu, L | 1 |
| Wood, RI | 1 |
| Licht, RW | 2 |
| Larsen, JO | 2 |
| Smith, D | 2 |
| Braendgaard, H | 2 |
| Mow, T | 1 |
| Kreilgaard, M | 1 |
| Velschow, S | 1 |
| Ohara, K | 1 |
| Shibuya, H | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Levant, B | 1 |
| Radel, JD | 1 |
| Carlson, SE | 1 |
| Hamilton, ME | 1 |
| Freeman, AS | 1 |
| Shimoda, K | 1 |
| Scherer, J | 1 |
| Dobmeier, P | 1 |
| Kuhn, K | 1 |
| Schmaus, W | 1 |
| Buchanan, RW | 1 |
| Ball, MP | 1 |
| Weiner, E | 1 |
| Kirkpatrick, B | 1 |
| Gold, JM | 1 |
| McMahon, RP | 1 |
| Carpenter, WT | 1 |
| Kinkead, B | 1 |
| Dobner, PR | 1 |
| Egnatashvili, V | 1 |
| Murray, T | 1 |
| Deitemeyer, N | 1 |
| Nemeroff, CB | 1 |
| Minet-Ringuet, J | 2 |
| Even, PC | 2 |
| Guesdon, B | 1 |
| Tomé, D | 2 |
| de Beaurepaire, R | 2 |
| Schleimer, SB | 1 |
| Johnston, GA | 1 |
| Henderson, JM | 1 |
| Alamy, M | 1 |
| Errami, M | 1 |
| Taghzouti, K | 1 |
| Saddiki-Traki, F | 1 |
| Bengelloun, WA | 1 |
| Vieta, E | 1 |
| Bourin, M | 1 |
| Sanchez, R | 1 |
| Marcus, R | 1 |
| Stock, E | 1 |
| McQuade, R | 1 |
| Carson, W | 1 |
| Abou-Gharbia, N | 1 |
| Swanink, R | 1 |
| Iwamoto, T | 1 |
| Lacroix, M | 1 |
| Guha, P | 1 |
| Roy, K | 1 |
| Sanyal, D | 1 |
| Dasgupta, T | 1 |
| Bhattacharya, K | 1 |
| Wang, JH | 1 |
| Yang, JZ | 1 |
| Wilson, FA | 1 |
| Ma, YY | 1 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Theisen, FM | 1 |
| Haberhausen, M | 1 |
| Firnges, MA | 1 |
| Gregory, P | 1 |
| Reinders, JH | 1 |
| Remschmidt, H | 1 |
| Hebebrand, J | 1 |
| Antel, J | 1 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
| Tulipano, G | 1 |
| Rizzetti, C | 1 |
| Bianchi, I | 1 |
| Fanzani, A | 1 |
| Spano, P | 1 |
| Cocchi, D | 1 |
| Bishnoi, M | 2 |
| Kumar, A | 1 |
| Chopra, K | 2 |
| Kulkarni, SK | 2 |
| Kim, B | 1 |
| Kim, SJ | 1 |
| Son, JI | 1 |
| Joo, YH | 1 |
| Chertkow, Y | 1 |
| Weinreb, O | 1 |
| Youdim, MB | 1 |
| Silver, H | 1 |
| Chaudhry, IB | 1 |
| Husain, N | 1 |
| Khan, S | 1 |
| Badshah, S | 1 |
| Deakin, B | 1 |
| Kapur, S | 1 |
| Saddichha, S | 1 |
| Manjunatha, N | 1 |
| Ameen, S | 1 |
| Akhtar, S | 1 |
| Huot, J | 1 |
| Bordeleau, JM | 1 |
| Tetreault, L | 2 |
| Bhargava, HN | 1 |
| Imai, S | 1 |
| Tauchi, K | 1 |
| Huang, KJ | 1 |
| Takeshima, T | 1 |
| Sudo, T | 1 |
| Staunton, DA | 1 |
| Magistretti, PJ | 1 |
| Shoemaker, WJ | 1 |
| Bloom, FE | 1 |
| Rupniak, NM | 3 |
| Mann, S | 2 |
| Hall, MD | 2 |
| Fleminger, S | 2 |
| Kilpatrick, G | 2 |
| Jenner, P | 3 |
| Marsden, CD | 3 |
| Overstreet, DH | 1 |
| Crocker, AD | 1 |
| Lawson, CA | 1 |
| McIntosh, GH | 1 |
| Crocker, JM | 1 |
| Donoso, A | 1 |
| Vera, G | 1 |
| Arancibia, A | 1 |
| Díaz, E | 1 |
| Schilkrut, R | 1 |
| Miserda, R | 1 |
| Kohen, P | 1 |
| Pak, N | 1 |
| Scatton, B | 1 |
| Fage, D | 1 |
| Spear, LP | 2 |
| Shalaby, IA | 1 |
| Brick, J | 1 |
| Waddington, JL | 1 |
| Gamble, SJ | 1 |
| Sylvester, PW | 1 |
| Aylsworth, CF | 1 |
| Meites, J | 4 |
| Uguru-Okorie, DC | 1 |
| Cuomo, V | 1 |
| Cagiano, R | 1 |
| Coen, E | 1 |
| Mocchetti, I | 1 |
| Cattabeni, F | 1 |
| Racagni, G | 1 |
| Leung, FC | 1 |
| Alysworth, CF | 1 |
| Bhanot, R | 1 |
| Wilkinson, M | 1 |
| Hruska, RE | 1 |
| Pitman, KT | 1 |
| Campbell, A | 1 |
| Baldessarini, RJ | 2 |
| Sethi, N | 1 |
| Prakash, R | 1 |
| Sethi, BB | 1 |
| Bourson, A | 1 |
| Borroni, E | 1 |
| Austin, RH | 1 |
| Monsma, FJ | 1 |
| Sleight, AJ | 1 |
| ThyagaRajan, S | 1 |
| Quadri, SK | 3 |
| Sebens, JB | 1 |
| Koch, T | 1 |
| Ter Horst, GJ | 1 |
| Korf, J | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Holson, RR | 2 |
| Webb, PJ | 1 |
| Grafton, TF | 1 |
| Hansen, DK | 1 |
| Silva, RR | 1 |
| Malone, RP | 1 |
| Anderson, LT | 1 |
| Shay, J | 1 |
| Campbell, M | 1 |
| Imanishi, M | 1 |
| Yoneyama, M | 1 |
| Takagi, S | 2 |
| Takeuchi, M | 2 |
| Kosten, TA | 1 |
| DeCaprio, JL | 1 |
| Nestler, EJ | 1 |
| Lane, HY | 1 |
| Chang, WH | 1 |
| Chang, YC | 1 |
| Hu, OY | 1 |
| Lin, HN | 1 |
| Jann, MW | 1 |
| Hu, WH | 1 |
| MohanKumar, PS | 1 |
| MohanKumar, SM | 1 |
| Arbogast, L | 1 |
| Voogt, JL | 1 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 1 |
| Hinze-Selch, D | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Pollmächer, T | 1 |
| Hack, JB | 1 |
| Leviss, JA | 1 |
| Nelson, LS | 1 |
| Hoffman, RS | 1 |
| Sieklucka-Dziuba, M | 1 |
| Dziuba, J | 1 |
| Patyra, H | 1 |
| Kleinrok, Z | 1 |
| Angelucci, F | 1 |
| Mathé, AA | 1 |
| O'Connor, JC | 1 |
| Plowchalk, DR | 1 |
| Van Pelt, CS | 1 |
| Davis, LG | 1 |
| Cook, JC | 1 |
| Marty, MS | 1 |
| Crissman, JW | 1 |
| Carney, EW | 1 |
| Kinon, BJ | 2 |
| Basson, BR | 2 |
| Gilmore, JA | 2 |
| Tollefson, GD | 2 |
| Kohge, S | 1 |
| Hagi, S | 1 |
| Utsumi, H | 1 |
| Takegawa, K | 1 |
| Nagaoka, T | 1 |
| Hanada, S | 1 |
| Taylor, CC | 1 |
| Szymanski, KA | 1 |
| Bunney, BS | 2 |
| Grace, AA | 1 |
| Baldino, F | 1 |
| Cowan, A | 1 |
| Geller, EB | 1 |
| Adler, MW | 1 |
| Doss, FW | 1 |
| Szabo, KT | 1 |
| Brent, RL | 1 |
| Chou, SM | 1 |
| Miike, T | 1 |
| Payne, WM | 1 |
| Davis, GJ | 1 |
| Skirboll, LR | 1 |
| Oldham, AJ | 1 |
| Janssen, PA | 2 |
| Niemegeers, CJ | 2 |
| Schellekens, KH | 1 |
| Lenaerts, FM | 1 |
| Wauquier, A | 1 |
| Wolgin, DL | 1 |
| Moore, J | 1 |
| Iishi, H | 1 |
| Baba, M | 1 |
| Tatsuta, M | 1 |
| Okuda, S | 1 |
| Taniguchi, H | 1 |
| Anderson, LL | 1 |
| Ford, JJ | 1 |
| Klindt, J | 1 |
| Molina, JR | 1 |
| Vale, WW | 1 |
| Rivier, J | 1 |
| Drucker-Colín, R | 1 |
| García-Hernández, F | 1 |
| Borker, AS | 1 |
| Mascarenhas, JF | 1 |
| Van Gent, CM | 1 |
| Sandberg, LB | 1 |
| Boucek, RJ | 1 |
| Miller-Podraza, H | 1 |
| Rakowska, M | 1 |
| Skarzyńska, E | 1 |
| Wolffgramm, J | 1 |
| Rommelspacher, H | 1 |
| Buck, E | 1 |
| See, RE | 1 |
| Ellison, G | 1 |
| Nylander, I | 1 |
| Terenius, L | 1 |
| Mitsushio, H | 1 |
| Takashima, M | 1 |
| Mataga, N | 1 |
| Toru, M | 1 |
| Nobrega, JN | 1 |
| Dixon, LM | 1 |
| Troncone, LR | 1 |
| Barros, HT | 1 |
| Prasad, C | 1 |
| Spahn, SA | 1 |
| Ikegami, H | 1 |
| Scalzo, FM | 2 |
| Gough, BJ | 1 |
| Ali, SF | 1 |
| Halperin, R | 1 |
| Guerin, JJ | 1 |
| Davis, KL | 1 |
| Saku, K | 1 |
| Sasaki, J | 1 |
| Arakawa, K | 1 |
| Ghadirian, AM | 1 |
| Nair, NP | 1 |
| Schwartz, G | 1 |
| De Vry, J | 1 |
| Donselaar, I | 1 |
| Van Ree, JM | 1 |
| McMillen, BA | 1 |
| Nakanishi, H | 1 |
| Tönjes, R | 1 |
| Dörner, G | 1 |
| Fujii, T | 1 |
| Okinaga, S | 1 |
| Ushijima, I | 1 |
| Mizuki, Y | 1 |
| Hara, T | 1 |
| Watanabe, K | 1 |
| Hirano, H | 1 |
| Yamada, M | 1 |
| Glavin, GB | 1 |
| Levy, AD | 1 |
| Ellison, GD | 1 |
| Najam, N | 1 |
| Cookson, JC | 1 |
| Kennedy, NM | 1 |
| Gribbon, D | 1 |
| Prestwich, SA | 1 |
| Horton, RW | 1 |
| Parati, EA | 1 |
| Parenti, M | 1 |
| Locatelli, V | 1 |
| Penalva, A | 1 |
| Tamminga, C | 1 |
| Müller, EE | 1 |
| Holtzman, SG | 1 |
| Hruban, Z | 1 |
| Mochizuki, Y | 1 |
| Goto, M | 1 |
| Slesers, A | 1 |
| Chou, SH | 1 |
| Cicero, TJ | 1 |
| Meyer, ER | 1 |
| Bell, RD | 1 |
| Chouinard, G | 1 |
| Serrano, PM | 1 |
| Opitz, K | 1 |
| Akinlaja, A | 1 |
| Agrawal, HC | 1 |
| Davis, JM | 1 |
| Haynes, EE | 1 |
| Himwich, WA | 1 |
| Ziv, G | 1 |
| Mishkinsky, JS | 1 |
| Givant, Y | 1 |
| Buchman, O | 1 |
| Sulman, FG | 1 |
| Tarsy, D | 1 |
| Serafetinides, EA | 1 |
| Collins, S | 1 |
| Clark, ML | 1 |
| Clark, JL | 1 |
| Sangiovanni, F | 1 |
| Taylor, MA | 1 |
| Abrams, R | 1 |
| Gaztanaga, P | 1 |
| Gjessing, LR | 1 |
| Martin, WR | 1 |
| Eades, CG | 1 |
| Thompson, WO | 1 |
| Thompson, JA | 1 |
| Flanary, HG | 1 |
| Boris, A | 1 |
| Milmore, J | 1 |
| Trmal, T | 1 |
| Einer-Jensen, N | 1 |
| Secher, NJ | 1 |
| Kondaurov, VN | 1 |
| Lappo, VG | 1 |
| Holland, JM | 1 |
| Gosslee, DG | 1 |
| Williams, NJ | 1 |
| Petrov, P | 1 |
| Bernhard, W | 1 |
| Huggler, AH | 2 |
| Schreiber, A | 2 |
| Dietschi, C | 2 |
| Jacob, H | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183] | 2,006 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation[NCT05351333] | 66 participants (Anticipated) | Interventional | 2022-08-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for haloperidol and Body Weight
| Article | Year |
|---|---|
[Effect of factors on plasma haloperidol concentration/dose ratio].
Topics: Aging; Antipsychotic Agents; Body Weight; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
[Effect of smoking on pharmacokinetics of antipsychotics].
Topics: Antipsychotic Agents; Body Weight; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Halope | 2004 |
13 trials available for haloperidol and Body Weight
| Article | Year |
|---|---|
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body | 2011 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio | 2004 |
Olanzapine treatment of residual positive and negative symptoms.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2005 |
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body W | 2005 |
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Diabetes | 2005 |
Amoxapine as an antipsychotic: comparative study versus haloperidol.
Topics: Adolescent; Adult; Age Factors; Amoxapine; Antidepressive Agents, Second-Generation; Antipsychotic A | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti | 2007 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Topics: Adult; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Fema | 1986 |
Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Bilirubin; Blood Cell Count | 1972 |
125 other studies available for haloperidol and Body Weight
| Article | Year |
|---|---|
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go | 2018 |
Central dopamine D2 receptors regulate growth-hormone-dependent body growth and pheromone signaling to conspecific males.
Topics: Analysis of Variance; Animals; Benzamides; Body Size; Body Weight; Case-Control Studies; Catatonia; | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat.
Topics: Alcohol Drinking; Alcoholism; Animals; Antipsychotic Agents; Body Weight; Clozapine; Dose-Response R | 2013 |
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Body Weight; Grooming; Haloperidol; Hand | 2015 |
High-fat diet alters weight, caloric intake, and haloperidol sensitivity in the context of effort-based responding.
Topics: Animals; Body Weight; Diet, High-Fat; Dietary Fats; Dopamine; Energy Intake; Feeding Behavior; Halop | 2017 |
Clozapine or Haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations.
Topics: Alkylating Agents; Animals; Antipsychotic Agents; Body Weight; Brain Chemistry; Clozapine; Entorhina | 2008 |
Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Weight; Brain Chemistry; Cholesterol; Cloz | 2010 |
Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus.
Topics: Adipocytes; Animals; Antimetabolites; Antipsychotic Agents; Benzodiazepines; Biomarkers; Body Temper | 2010 |
Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice.
Topics: Animals; Body Weight; Caloric Restriction; Dietary Fats; Dopamine Antagonists; Dopamine D2 Receptor | 2011 |
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Ant | 2011 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocain | 2013 |
The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model.
Topics: Adiposity; Animals; Antipsychotic Agents; Blood Glucose; Body Weight; Clozapine; Drinking; Eating; F | 2013 |
Differential activation of orexin neurons by antipsychotic drugs associated with weight gain.
Topics: Amphetamine; Animals; Antipsychotic Agents; Body Weight; Carrier Proteins; Cell Count; Central Nervo | 2002 |
Effects of dopamine receptor antagonism with haloperidol on nurturing behavior in the biparental prairie vole.
Topics: Animals; Arvicolinae; Body Weight; Brain Chemistry; Dopamine Antagonists; Dose-Response Relationship | 2002 |
Castration, dopamine and food choice: a cost/benefit test in male hamsters.
Topics: Animals; Body Weight; Choice Behavior; Conditioning, Operant; Cost-Benefit Analysis; Cricetinae; Dop | 2002 |
Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellum.
Topics: Animals; Antipsychotic Agents; Body Weight; Cell Count; Cell Size; Cerebellum; Female; Haloperidol; | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Resp | 2003 |
Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain; | 2004 |
Diet and chronic haloperidol effects on rat midbrain dopamine neurons.
Topics: Action Potentials; Animals; Antipsychotic Agents; Body Weight; Diet; Dopamine; Eating; Electrophysio | 2004 |
Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Dibenzothiazepi | 2005 |
Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Blood Glucose; Bod | 2005 |
Novel oral drug administration in an animal model of neuroleptic therapy.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Clozapine | 2005 |
Effects of postweaning undernutrition on exploratory behavior, memory and sensory reactivity in rats: implication of the dopaminergic system.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain Chemistry; Chromatography, High Pres | 2005 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Die | 2006 |
Differently lasting effects of prenatal and postnatal chronic clozapine/haloperidol on activity and memory in mouse offspring.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Body Weight; Central Nervous Sy | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Haloperidol; Humans; Olanzap | 2007 |
Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice.
Topics: Animals; Animals, Newborn; Apomorphine; Behavior, Animal; Body Weight; Dopamine Agonists; Dopamine A | 2006 |
Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Weight; Clozapine; Corticosterone; Eating; Female | 2007 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-In | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A | 2008 |
Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Clozapine; Dopamine; Dopamine A | 2007 |
Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Topics: Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Antipsychotic Agents; Behavior, Animal; Body W | 2008 |
Haloperidol and blood cholesterol: a cross-sectional survey in a psychiatric hospital.
Topics: Age Factors; Body Height; Body Weight; Cholesterol; Female; Haloperidol; Humans; Male; Menopause; Me | 1967 |
Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
Topics: Animals; Apomorphine; Body Weight; Cell Membrane; Corpus Striatum; Dipeptides; Haloperidol; In Vitro | 1984 |
[Teratogenicity study on bromperidol in rats].
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Body | 1984 |
Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. I. Locomotor activity and behavioral supersensitivity.
Topics: Animals; Apomorphine; Body Weight; Chlorides; Corpus Striatum; Eating; Haloperidol; Humans; Lithium; | 1982 |
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
Topics: Acetylcholine; Animals; Apomorphine; Body Weight; Corpus Striatum; Haloperidol; Humans; Kinetics; Ma | 1984 |
Alterations in the dopaminergic system and behaviour in rats reared on iodine-deficient diets.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Body Temperature; Body Weight; Brain Che | 1984 |
[Influence of nutritional status on intravenous pharmacokinetics of haloperidol in psychotic patients].
Topics: Adult; Body Height; Body Weight; Chronic Disease; Haloperidol; Humans; Injections, Intravenous; Iron | 1984 |
Hypophysectomy fails to affect the supersensitivity of striatal dopamine target cells induced by prolonged haloperidol treatment.
Topics: Acetylcholine; Animals; Apomorphine; Body Weight; Brain Chemistry; Corpus Striatum; Dopamine; Ergoli | 1984 |
Chronic administration of haloperidol during development: behavioral and psychopharmacological effects.
Topics: Animals; Behavior, Animal; Birth Weight; Body Weight; Brain Chemistry; Catalepsy; Female; Fertility; | 1980 |
Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.
Topics: Animals; Apomorphine; Body Weight; Haloperidol; Humans; Male; Motor Activity; Rats; Stereotyped Beha | 1980 |
Relationship of hormones to inhibition of mammary tumor development by underfeeding during the "critical period" after carcinogen administration.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Body Weight; Diet; Estradiol; Fasting; Female; Growth Hor | 1981 |
Effects of chronic haloperidol treatment on ingestive behaviour and body weight regulation in the rat.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drinking; Eating; Feces; Feeding Behavior; H | 1981 |
Enduring behavioural and biochemical effects in the adult rat after prolonged postnatal administration of haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Female; Hal | 1981 |
Counteraction of underfeeding-induced inhibition of mammary tumor growth in rats by prolactin and estrogen administration.
Topics: Animals; Body Weight; Estradiol; Female; Haloperidol; Mammary Neoplasms, Experimental; Nutrition Dis | 1983 |
Treatment of pregnant rats with haloperidol delays the onset of sexual maturation in female offspring.
Topics: Animals; Body Weight; Female; Haloperidol; Male; Pregnancy; Pregnancy, Animal; Prenatal Exposure Del | 1982 |
Hypophysectomy reduces the haloperidol-induced changes in striatal dopamine receptor density.
Topics: Analysis of Variance; Animals; Body Weight; Corpus Striatum; Haloperidol; Hypophysectomy; Male; Prol | 1982 |
Tolerance to behavioral effects of haloperidol.
Topics: Animals; Behavior, Animal; Blepharoptosis; Body Weight; Catalepsy; Drug Tolerance; Growth; Haloperid | 1981 |
Effects of administration of haloperidol with lithium in rabbits.
Topics: Animals; Body Weight; Brain; Drug Therapy, Combination; Female; Haloperidol; Lithium; Male; Rabbits | 1981 |
Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Base Sequence; Body Temperature; Body Weight; Bra | 1995 |
Underfeeding-induced suppression of mammary tumors: counteraction by estrogen and haloperidol.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Body Weight; Dopamine; Estradiol; Female; Food Deprivatio | 1993 |
Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment.
Topics: Animals; Body Weight; Catalepsy; Clozapine; Haloperidol; Immunohistochemistry; Male; Prosencephalon; | 1995 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzazepines; Body Weight; Brain; Dopamine D2 R | 1994 |
Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex.
Topics: Animals; Body Weight; Cell Count; Cell Size; Cerebral Cortex; Female; Haloperidol; Histocytochemistr | 1994 |
Haloperidol withdrawal and weight changes in autistic children.
Topics: Autistic Disorder; Body Weight; Child; Child, Preschool; Female; Haloperidol; Humans; Male; Prospect | 1993 |
Collaborative work to determine an optimal administration period and optimal parameters for detection of effects on male fertility in rats--male reproductive toxicity study of haloperidol.
Topics: Animals; Body Weight; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration Schedu | 1995 |
Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Cocaine; Conditioning, Operant; Discri | 1996 |
Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesia, | 1997 |
Effects of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Body Weight; Dopamine; Dopamine Antagonists; Estrus; Femal | 1998 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 1999 |
Severe symptoms following a massive intentional L-thyroxine ingestion.
Topics: Adult; Antidotes; Body Weight; Charcoal; Diazepam; Haloperidol; Humans; Intubation, Intratracheal; M | 1999 |
Central action of some cytostatics--methotrexate (MTX) and doxorubicin (DXR). I. Long-term influence on the pain sensitivity and activity of brain dopaminergic system in mice.
Topics: Analgesics; Animals; Behavior, Animal; Body Weight; Brain; Catalepsy; Doxorubicin; Drug Interactions | 1998 |
Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration.
Topics: Animals; Antipsychotic Agents; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Feeding Behavi | 2000 |
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.
Topics: Adrenergic Uptake Inhibitors; Animals; Atrazine; Biological Assay; Body Weight; Dopamine Antagonists | 2000 |
Evaluation of the male pubertal assay's ability to detect thyroid inhibitors and dopaminergic agents.
Topics: Animals; Antithyroid Agents; Body Weight; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Ge | 2001 |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 6). 2- and 4-weeks administration study of haloperidol.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; | 2000 |
Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity.
Topics: Animals; Apomorphine; Body Weight; Dopamine; gamma-Aminobutyric Acid; Glutamates; Haloperidol; Kaini | 1978 |
Effects of antipsychotic and antianxiety drugs on the morphine abstinence syndrome in rats.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Chlordiazepoxide; | 1979 |
The effect of antipsychotic drugs on body weight: a retrospective review.
Topics: Antipsychotic Agents; Body Weight; Fluphenazine; Haloperidol; Humans; Loxapine; Schizophrenia; Thior | 1979 |
Letter: Reduction of drug-induced cleft palate in mice.
Topics: Animals; Body Weight; Cleft Palate; Feeding Behavior; Female; Food Deprivation; Haloperidol; Materna | 1975 |
Neuropathology of "spinning syndrome" induced by prenatal intoxication with a PCB in mice.
Topics: Animals; Animals, Newborn; Apomorphine; Body Weight; Central Nervous System Diseases; Cranial Nerves | 1979 |
The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the rat.
Topics: Animals; Behavior, Animal; Body Weight; Caudate Nucleus; Dopamine; Electrophysiology; Haloperidol; M | 1979 |
The rapid control of the acute patient by haloperidol.
Topics: Acute Disease; Age Factors; Body Weight; Female; Haloperidol; Humans; Male; Mental Disorders; Sex Fa | 1976 |
Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Tem | 1975 |
Sensitization to haloperidol-induced suppression of milk intake: effect of interdose interval.
Topics: Animals; Body Weight; Depression, Chemical; Dose-Response Relationship, Drug; Drinking Behavior; Hal | 1992 |
Inhibition by the dopamine antagonist haloperidol of experimental carcinogenesis induced by azoxymethane in rat colon.
Topics: Adenocarcinoma; Animals; Azoxymethane; Body Weight; Bromocriptine; Colonic Neoplasms; Cyclic AMP; DN | 1991 |
Growth hormone and prolactin secretion in hypophysial stalk-transected pigs as affected by growth hormone and prolactin-releasing and inhibiting factors.
Topics: Adrenal Glands; alpha-Methyltyrosine; Animals; Arginine; Body Weight; Female; Growth Hormone; Growth | 1991 |
A new motor test sensitive to aging and dopaminergic function.
Topics: Aging; Animals; Body Weight; Dextroamphetamine; Dopamine; Haloperidol; Levodopa; Male; Motor Activit | 1991 |
Role of acetylcholine and dopamine in dorsal hippocampus on hoarding behavior in rats.
Topics: Acetylcholine; Animals; Apomorphine; Atropine; Behavior, Animal; Body Weight; Dopamine; Eating; Estr | 1991 |
Haloperidol administration to rats during pregnancy induces permanent alterations in serum lipoprotein patterns of progeny.
Topics: Animals; Body Weight; Brain; Cholesterol; Female; Haloperidol; Lipoproteins; Male; Pregnancy; Prenat | 1991 |
Lack of major effects of ethanol, chlorpromazine, hexobarbital and haloperidol on brain gangliosides.
Topics: Animals; Body Weight; Brain; Chlorpromazine; Ethanol; Gangliosides; Haloperidol; Hexobarbital; Male; | 1990 |
Ethanol reduces tolerance, sensitization, and up-regulation of D2-receptors after subchronic haloperidol.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Drug Toleranc | 1990 |
Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Body Weight; Clozapine; Dibenzazepines; Disease Models, Animal; Drinking; | 1990 |
Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat.
Topics: Animals; Basal Ganglia; Body Weight; Clozapine; Dibenzazepines; Dynorphins; Haloperidol; Injections, | 1986 |
Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
Topics: Animals; Body Weight; Brain Chemistry; Carbamazepine; Dopamine; Dose-Response Relationship, Drug; ga | 1988 |
Effects of chronic haloperidol on stress-induced oral behaviour in rats.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Corpus Striatum; Feeding Behavior; Haloperidol; | 1989 |
Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
Topics: Animals; Body Weight; Corpus Striatum; Dyskinesia, Drug-Induced; Eating; Haloperidol; Male; Nicotine | 1989 |
Neurochemical effects of prenatal haloperidol exposure.
Topics: Amphetamine; Animals; Body Weight; Brain Chemistry; Female; Haloperidol; Male; Pregnancy; Pregnancy | 1989 |
Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Clozapine; Corpus Striatum; Dopamine; | 1989 |
Lack of effect of chlorpromazine and haloperidol on serum lipid levels and on atherogenesis in cholesterol fed rabbits.
Topics: Animals; Arteriosclerosis; Body Weight; Chlorpromazine; Cholesterol; Cholesterol, Dietary; Haloperid | 1989 |
Effect of lithium and neuroleptic combination on lithium transport, blood pressure, and weight in bipolar patients.
Topics: Adult; Aged; Bipolar Disorder; Blood Pressure; Body Weight; Chlorpromazine; Dose-Response Relationsh | 1989 |
Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol.
Topics: Animals; Body Weight; Cocaine; Food Deprivation; Haloperidol; Male; Naltrexone; Rats; Rats, Inbred S | 1989 |
Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Body Weight; Bus | 1985 |
Effects of neuroleptics administered to lactating rats on the behavioral development of offspring.
Topics: Animals; Animals, Suckling; Antipsychotic Agents; Behavior, Animal; Body Weight; Diazepam; Female; G | 1986 |
Effects of acute and long-term treatments with thyrotropin-releasing hormone on locomotor activity and jumping behavior in mice.
Topics: Animals; Apomorphine; Body Weight; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; | 1986 |
Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Drug Interactions; Dyskinesia, Drug-Induced; Fe | 1987 |
Involvement of dopaminergic systems in the ventromedial hypothalamic hyperphagia.
Topics: Animals; Body Weight; Dopamine; Eating; Female; Haloperidol; Hyperphagia; Rats; Rats, Inbred Strains | 1988 |
Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine.
Topics: Animals; Body Weight; Brain; Clozapine; Flunitrazepam; gamma-Aminobutyric Acid; Glutamate Decarboxyl | 1987 |
Chronic haloperidol during development attenuates dopamine autoreceptor function in striatal and mesolimbic brain regions of young and older adult rats.
Topics: 4-Butyrolactone; Aging; Animals; Body Weight; Corpus Striatum; Dopamine; Female; Haloperidol; Limbic | 1985 |
Failure of chronic haloperidol to affect prolactin secretion due to acute haloperidol administration.
Topics: Animals; Body Weight; Corpus Striatum; Haloperidol; Kinetics; Male; Pituitary Gland; Prolactin; Radi | 1985 |
Discriminative stimulus effects of morphine withdrawal in the dependent rat: suppression by opiate and nonopiate drugs.
Topics: Animals; Body Weight; Clonidine; Haloperidol; Humans; Male; Morphine Dependence; Naloxone; Naltrexon | 1985 |
Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
Topics: Acetylcholine; Animals; Apomorphine; Body Weight; Clozapine; Corpus Striatum; Dibenzazepines; Halope | 1985 |
Effects of some hypocholesterolemic agents on hepatic ulrastructure and microbody enzymes.
Topics: Amino Acid Oxidoreductases; Animals; Anticholesteremic Agents; Benzimidazoles; Body Weight; Catalase | 1974 |
Effects of phenoxybenzamine on the narcotic withdrawal syndrome in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Behavior, Animal; Body Weight; Chlorpromazine; Depression, Che | 1974 |
Potentiation of haloperidol by -methyldopa in the treatment of schizophrenic patients.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Blood Pressure; Body Weight; Drug Synergism; Fe | 1973 |
[On the influencing of food intake by psychotropic drugs].
Topics: Amitriptyline; Animals; Behavior, Animal; Body Weight; Central Nervous System; Central Nervous Syste | 1966 |
Chlorpromazine and GABA.
Topics: Amino Acids; Aminobutyrates; Animals; Blood; Body Weight; Brain; Brain Chemistry; Cerebellum; Cerebr | 1969 |
Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Bleph | 1974 |
Distribution of tritiated haloperidol in lactating and pregnant cows and ewes.
Topics: Animals; Body Weight; Cattle; Female; Haloperidol; Injections, Intramuscular; Injections, Intravenou | 1974 |
Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.
Topics: Animals; Apomorphine; Behavior, Animal; Body Weight; Catecholamines; Chlorpromazine; Diazepam; Dose- | 1974 |
Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats.
Topics: Animals; Benz(a)Anthracenes; Body Weight; Female; Haloperidol; Injections, Subcutaneous; Lysergic Ac | 1973 |
Rapid control of psychotic excitement states with intramuscular haloperidol.
Topics: Acute Disease; Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Female; Halo | 1973 |
A review of periodic catatonia.
Topics: Age Factors; Animals; Arousal; Basal Metabolism; Body Temperature; Body Weight; Catatonia; Chlorprom | 1974 |
Morphine physical dependence in the dog.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Dogs; Dose-Response Relationship, Drug; Ha | 1974 |
Some effects of haloperidol on reproductive organs in the female rat.
Topics: Animals; Body Weight; Castration; Depression, Chemical; Estrogen Antagonists; Female; Gonadotropins; | 1970 |
Diminished weight of rat foetuses after treatment of pregnant rats with haloperidol.
Topics: Animals; Body Weight; Embryo Implantation; Female; Fertilization; Fetus; Haloperidol; Parity; Pregna | 1970 |
[Methods of assessing the toxic properties of polymeric filling materials (author's transl)].
Topics: Alcohol Drinking; Animals; Body Weight; Cell Count; Eosinophils; Epoxy Resins; Guinea Pigs; Histamin | 1978 |
Epidermal carcinogenicity of bis(2,3-epoxycyclopentyl)ether, 2,2-bis(p-glycidyloxyphenyl)propane, and m-phenylenediamine in male and female C3H and C57BL/6 mice.
Topics: Animals; Benzhydryl Compounds; Benzopyrenes; Body Weight; Carcinogens; Dose-Response Relationship, D | 1979 |
Experimentally induced changes of extranucleolar ribonucleoprotein components of the interphase nucleus.
Topics: Adrenalectomy; Aldehydes; Animals; Body Weight; Cell Nucleus; Cortisone; Diet; Edetic Acid; Epoxy Re | 1971 |
[Experimental investigation of deformation of the weightbearing acetabulum (author's transl)].
Topics: Acetabulum; Biodegradation, Environmental; Biomechanical Phenomena; Body Weight; Epoxy Resins; Human | 1974 |
[Proceedings: Experimental studies of the deformation of the acetabulum under stress].
Topics: Acetabulum; Biomechanical Phenomena; Body Weight; Epoxy Resins; Hip Joint; Humans; Joint Prosthesis; | 1974 |